One of the creators of a Cvodi-19 vaccine has said that there would be significant impact on the lives of people of the new Covid-19 vaccine over summer and by winter next year, life should be back to normal.
Since the vaccine would not have a big impact on infection numbers, therefore this winter would still be hard, said Prof Ugur Sahin, the co-founder of BioNTech.
The vaccine candidate being developed by BioNTech jointly with Pfizer had exhibited capacity to could prevent more than 90 per cent of people from getting Covid-19, the company had announced last week.
About 43,000 people took part in those last stage trials.
The vaccine is to be given in two doses at durations of three weeks.
Various governments have said that the first doses of the vaccine would be given to older residents and staff in care homes and then health workers and the over-80s would be prioritized.
In addition to reducing transmission between people, Prof Sahin was very confident of the be wCovid-19 vaccine also being able to prevent development of symptoms of the disease in people who has had the vaccine, he said in a television interview.
It is also a possibility that transmission could get reduced by 50 per cent by the vaccine which would create a huge impact. he said.
“I’m very confident that transmission between people will be reduced by such a highly effective vaccine – maybe not 90% but maybe 50% – but we should not forget that even that could result in a dramatic reduction of the pandemic spread,” he added.
Life could be back to normal by spring, Sir John Bell, regius professor of medicine at Oxford University, had suggested after the announcement of the first effective vaccine of the world was made on Monday.
“I am probably the first guy to say that, but I will say that with some confidence,” he said.
But according to Prof Sahin, a longer time would be required for people to get back to their normal lives.
It would be possible to start delivering the vaccine at the “end of this year, beginning of next year” if everything continued to go well, he said.
He added that the vaccine developers aimed to be able to deliver over 300 million doses of the vaccine globally by next April which “could allow us to only start to make an impact”.
The bigger impact would happen later, he said.
“Summer will help us because the infection rate will go down in the summer and what is absolutely essential is that we get a high vaccination rate until or before autumn/winter next year,” he added.
Before next autumn, it was essential that all immunisation programmes, Prof Sahin said.
With respect to concerns of whether the vaccine would be as effective on older people as it is on younger ones, he said that answer to that question will become clearer in the next three weeks.
The length of time the immunity delivered by the vaccine would last is not yet clear, he said.
(Adapted from BBC.com)